Table 2.
Prostate cancer detection rate stratified by age, prostate-specific antigen value, and prostate volume before and after propensity score matching
| Groups | Unmatched | Propensity score matched | ||||
|---|---|---|---|---|---|---|
| Detection rate in TRBx | Detection rate in TPBx | P | Detection rate in TRBx | Detection rate in TPBx | P | |
| Overall detection rate, n/total (%) | 524/1216 (43.1) | 785/1746 (45.0) | 0.314 | 184/376 (48.9) | 182/376 (48.4) | 0.884 |
| Age (year), n/total (%) | ||||||
| ≤59 | 24/122 (19.7) | 50/206 (24.3) | 0.335 | 5/33 (15.2) | 13/41 (31.7) | 0.099 |
| 60–69 | 176/550 (32.0) | 226/585 (38.6) | 0.020 | 57/156 (36.5) | 40/97 (41.2) | 0.455 |
| 70–79 | 212/398 (53.3) | 380/728 (52.2) | 0.731 | 81/136 (59.6) | 77/146 (52.7) | 0.249 |
| ≥80 | 112/146 (76.7) | 129/227 (56.8) | <0.001 | 41/51 (80.4) | 52/92 (56.5) | 0.004 |
| PSA (ng ml−1), n/total (%) | ||||||
| ≤4.0 | 14/103 (13.6) | 16/98 (16.3) | 0.587 | 7/30 (23.3) | 2/14 (14.3) | 0.695a |
| 4.1–10.0 | 103/430 (24.0) | 101/416 (24.3) | 0.912 | 40/138 (29.0) | 25/83 (30.1) | 0.858 |
| 10.1–20.0 | 136/327 (41.6) | 134/472 (28.4) | <0.001 | 39/92 (42.4) | 38/111 (34.2) | 0.233 |
| 20.1–100.0 | 191/276 (69.2) | 258/479 (53.9) | <0.001 | 76/94 (80.9) | 114/165 (69.1) | 0.040 |
| >100.0 | 80/80 (100) | 276/281 (98.2) | 0.591a | 22/22 (100) | 3/3 (100) | NA |
| PV (ml), n/total (%) | ||||||
| <25 | 65/105 (61.9) | 146/249 (58.6) | 0.567 | 64/106 (60.4) | 57/106 (53.8) | 0.331 |
| 25≤PV<50 | 243/487 (49.9) | 360/765 (47.1) | 0.327 | 72/139 (51.8) | 71/138 (51.4) | 0.954 |
| 50≤PV<75 | 122/325 (37.5) | 202/477 (42.3) | 0.173 | 33/83 (39.8) | 40/86 (46.5) | 0.376 |
| ≥75 | 94/299 (31.4) | 77/255 (30.2) | 0.752 | 15/48 (31.2) | 14/46 (30.4) | 0.932 |
aFisher’s exact test. TRBx: transrectal biopsy; TPBx: transperineal biopsy; PSA: prostate-specific antigen; PV: prostate volume; NA: not available.